Vaidya Sane Ayurved Laboratories Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Revenue declined, strategy reset: H2 FY24 revenue fell 9.99% YoY as a marketing push toward prevention products brought in lower-ticket, non-diseased patients; management has corrected the strategy and cut costs.
• Cost actions already in motion: Annual salary expense is being reduced from ~₹27 cr to ~₹21–₹21.5 cr, with headcount cuts implemented 1–2 months ago; other expense lines also targeted for reduction.
• Acquisitions close, integration begins: UV Ayurgen and Dynamic Remedies acquisitions completed, promising a 20%–30% reduction in purchase cost once fully integrated.
• FY25 guided for sharp recovery: Management targets 15%–20% topline growth and EBITDA margin above 10%, calling the 10% figure "very conservative."
• What to watch next quarter: Whether the cost-reduction actions translate into margin improvement, the pace of new diseased-patient footfall after the Medulla tie-up, and any franchise-hospital deal announcements.

Revenue Decline & Strategy Correction

• H2 weakness: H2 FY24 revenue fell 9.99% YoY because marketing strategies directed toward Madhavprash brought footfall skewed to prevention-modality patients with lower ticket sizes, while care plan sales dropped by ~1,000–1,200 units YoY.
• Full-year flat: FY24 revenue was nearly flat (+0.16%) as H1 marketing-driven footfall maintained clinic collections but did not convert into high-value care plan sales.
• Strategy reset: Management has refocused marketing on attracting diseased patients for diabetes and heart care plans, and partnered with Medulla Communications for branding and focused treatment marketing.
• Care plan economics: The core model requires patients to stay for a full year on reversal-focused treatment, differentiating the company from competitors who do not target disease reversal.

Dr. Rohit Madhav Sane: "We are looking out for reversal of those diseases and for this we expect the patient to stay with us for the whole year."

Cost Reduction Program

• Salary expense cut: Annual salary expense being reduced from ~₹27 cr to ~₹21–₹21.5 cr; headcount reduction already implemented 1–2 months ago and the elevated cost will not continue next year.
• Other expense targets: Total other expenses planned to reduce from ~₹42 cr to ~₹38–₹39 cr, with professional fees dropping from ₹10 cr to ₹6–₹7 cr and travelling, training, repair expenses from ₹10 cr to ~₹7 cr.
• Purchase cost benefit: Direct vendor negotiations and the UV Ayurgen/Dynamic Remedies acquisitions are expected to reduce purchase cost by 20%–30%.
• Rent outlook: Rent may decline as company-owned clinics convert to franchise operations, though management conservatively holds the estimate at ₹7 cr.

Dr. Rohit Madhav Sane: "All these points will accumulate to improve the bottom line and the EBITDAs will improve that is of no question to me."

Acquisitions & Integration

• Two acquisitions closed: UV Ayurgen Pharma (food product manufacturing) and Dynamic Remedies (medicine manufacturing) acquisitions completed during the quarter.
• Purchase cost synergy: Management expects the whole purchase cost to reduce by 20%–30% due to these acquisitions, as backward integration eliminates third-party manufacturing margins.
• Production commenced: UV Ayurgen completed its first production batch of Madhavshakti Atta and Premeha Diet Kit; initial 2–3 months of inventory build explains the quarter's inventory increase.
• Short-term debt impact: Borrowing increased due to the acquisition funding and inter-company transactions; cost of debt rose on higher overdraft utilization.

Dr. Rohit Madhav Sane: "the whole purchase cost will reduce down by about 20% to 30% due to this acquisition"

Expansion Strategy: Hospitals Over Clinics

• Clinic target delayed: The Mission 2025 target of 1,000 clinics will now take 3–4 years; near-term clinic expansion shifts to franchise mode only, with 50–60 franchise clinics planned this year.
• Hospitals prioritized: Expansion investment this year will focus on hospitals, which management says can deliver much higher EBITDA than clinics.
• Khopoli expansion: Plan to add 100 more beds at Khopoli Hospital in the next 12–18 months, pending MSRDC approval.
• Vizag hospital: The new Madhavbaug Vishakhapatnam Hospital, opened 3 months ago in partnership with a state government entity, is performing well in a newer territory.
• Franchise hospital pipeline: Deals for franchise hospitals, where the company bears no expense but earns a revenue share, are in the pipeline and will be disclosed to exchanges in coming months.

Dr. Rohit Madhav Sane: "Hospitals can give much more higher EBITDA as compared to clinic, but at the same time clinic have presence in the local residential area of the patients vicinity."

Marketing & Patient Acquisition

• Medulla Communications tie-up: Partnership signed for branding and focused treatment marketing; management expects 20% growth in new patient footfall from this engagement.
• Marketing budget increase: Marketing spend planned to scale from ₹14–₹15 cr to ₹18–₹20 cr to drive topline growth.
• Product strategy: Madhavprash remains the only product pushed through the Dynamic Remedies subsidiary; core focus stays on diabetes and heart patient treatments through care plans, with new products like ghee sold only inside clinics, not retail.

Guidance & Commitments

Key Metrics